Clinical Trial Update: A Pilot Study to Evaluate the Lipid Effects of TRIA-662 [Phase 2]

View source ↗

Summary

A Phase 2 pilot trial evaluating the lipid effects of TRIA-662 in hypertriglyceridemia and mixed hyperlipidemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertriglyceridemia
• Mixed Hyperlipidemia

Drugs mentioned

• TRIA-662

Snippet

Sponsor: Cortria Corporation | Conditions: Hypertriglyceridemia, Mixed Hyperlipidemia | Phase 2 | Status: COMPLETED